These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 24814578

  • 1. Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.
    Li J, Jia M, Liu Y, She W, Li L, Wang J, Jiang W.
    Liver Int; 2015 Mar; 35(3):834-45. PubMed ID: 24814578
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
    Yang X, Li J, Liu J, Gao M, Zhou L, Lu W.
    Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA.
    Yan Z, Zhou J, Zhang M, Fu X, Wu Y, Wang Y.
    Mol Med Rep; 2014 May; 9(5):2024-30. PubMed ID: 24626572
    [Abstract] [Full Text] [Related]

  • 7. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W, Yang HH, Fan YM, Li T, Zhang LF, Mui C, Fan HW, Zhou BT, Liu ZY, Ng H, Liu XQ.
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
    Ma SW, Huang X, Li YY, Tang LB, Sun XF, Jiang XT, Zhang YX, Sun J, Liu ZH, Abbott WG, Dong YH, Naoumov NV, Hou JL.
    J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
    [Abstract] [Full Text] [Related]

  • 10. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL, Netherlands Association of Gastroenterologists and Hepatologists.
    Neth J Med; 2008 Apr; 66(7):292-306. PubMed ID: 18663260
    [Abstract] [Full Text] [Related]

  • 11. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.
    Wang GQ, Ding YP, Dong YH.
    J Viral Hepat; 2013 Apr; 20 Suppl 1():9-17. PubMed ID: 23458520
    [Abstract] [Full Text] [Related]

  • 12. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
    Sulaiman A, Lesmana LA, Nafrialdi, Helyanna.
    Acta Med Indones; 2014 Jan; 46(1):38-43. PubMed ID: 24760807
    [Abstract] [Full Text] [Related]

  • 13. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
    Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J.
    Hepatology; 2014 Apr; 59(4):1283-92. PubMed ID: 24382690
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C.
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [Abstract] [Full Text] [Related]

  • 16. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP.
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [Abstract] [Full Text] [Related]

  • 17. [The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B].
    Pan XC, Yang F, Chen M.
    Zhonghua Gan Zang Bing Za Zhi; 2008 Dec; 16(12):885-8. PubMed ID: 19105929
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
    Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH.
    Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection.
    Li Y, Ma S, Tang L, Li Y, Wang W, Huang X, Lai Q, Zhang M, Sun J, Li CK, Abbott WG, Naoumov NV, Zhang Y, Hou J.
    Hepatology; 2013 Oct; 58(4):1277-86. PubMed ID: 23703545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.